000142479 001__ 142479
000142479 005__ 20240229105148.0
000142479 0247_ $$2doi$$a10.1097/CMR.0000000000000435
000142479 0247_ $$2pmid$$apmid:29485532
000142479 0247_ $$2ISSN$$a0960-8931
000142479 0247_ $$2ISSN$$a1473-5636
000142479 0247_ $$2altmetric$$aaltmetric:33728487
000142479 037__ $$aDKFZ-2019-00198
000142479 041__ $$aeng
000142479 082__ $$a610
000142479 1001_ $$aMachiraju, Devayani$$b0
000142479 245__ $$aSTAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
000142479 260__ $$a[s.l.]$$bOvid$$c2018
000142479 3367_ $$2DRIVER$$aarticle
000142479 3367_ $$2DataCite$$aOutput Types/Journal article
000142479 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550214093_32760
000142479 3367_ $$2BibTeX$$aARTICLE
000142479 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142479 3367_ $$00$$2EndNote$$aJournal Article
000142479 520__ $$aInterferons (IFN) have a direct growth-inhibiting effect on tumor cells through Janus kinase-dependent activation of the transcription factor signal transducer and activator of transcription (STAT1). In vitro, signaling through STAT5 has been demonstrated to counteract this effect and lead to IFN resistance of melanoma cell lines. In 32 patients treated with IFN-α in an adjuvant setting, we investigated paraffin-embedded tumor tissue from primary melanomas and melanoma metastases for expression of STAT3 and STAT5, by immunohistochemistry, and for expression of phosphorylated signaling transduction activating transcription factor (pSTAT)3 and pSTAT5, by immunofluorescence. Tumor cell expression levels of these proteins were correlated with patient characteristics and clinical outcomes. The patient cohort consisted of 12 (37.5%) patients at AJCC stage I/II (primary melanoma) and 20 (62.5%) at stage III/IV (metastatic melanoma). Recurrence was observed for 25 (78.1%) either during or after IFN-α therapy. χ Correlation of staining intensities with clinical data revealed association of pSTAT3 and STAT5 expression with sex (P=0.003 and 0.016, respectively) and of STAT3 with tumor stage (P=0.019). Recurrence of melanoma was found to be associated with high STAT5 expression (P=0.017). Multivariable regression analysis revealed STAT5 expression as an independent factor for predicting progression-free survival (P<0.0001) and overall survival (P=0.022). In summary, high expression of STAT5 correlated with melanoma recurrence and survival of patients treated with IFN-α in the adjuvant setting. Recently, it has been suggested that mutations of Janus kinases are involved in resistance to immune checkpoint blocker treatments implying a possible role of STAT5 for immune checkpoint resistance.
000142479 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142479 588__ $$aDataset connected to CrossRef, PubMed,
000142479 650_7 $$2NLM Chemicals$$aInterferon-alpha
000142479 650_7 $$2NLM Chemicals$$aSTAT5 Transcription Factor
000142479 7001_ $$aMoll, Iris$$b1
000142479 7001_ $$0P:(DE-He78)d239d6a28875058b40c13266babadb58$$aGebhardt, Christoffer$$b2$$udkfz
000142479 7001_ $$aSucker, Antje$$b3
000142479 7001_ $$aBuder-Bakhaya, Kristina$$b4
000142479 7001_ $$aSchadendorf, Dirk$$b5
000142479 7001_ $$0P:(DE-He78)00858755eb8a7861491b50e2d00e52f1$$aHassel, Jessica$$b6$$eLast author$$udkfz
000142479 773__ $$0PERI:(DE-600)2030780-9$$a10.1097/CMR.0000000000000435$$gVol. 28, no. 3, p. 1 -$$n3$$p204-210$$tMelanoma research$$v28$$x0960-8931$$y2018
000142479 909CO $$ooai:inrepo02.dkfz.de:142479$$pVDB
000142479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d239d6a28875058b40c13266babadb58$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)00858755eb8a7861491b50e2d00e52f1$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142479 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142479 9141_ $$y2018
000142479 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000142479 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000142479 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMELANOMA RES : 2017
000142479 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142479 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142479 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142479 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142479 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142479 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142479 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142479 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142479 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142479 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142479 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000142479 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x0
000142479 980__ $$ajournal
000142479 980__ $$aVDB
000142479 980__ $$aI:(DE-He78)G300-20160331
000142479 980__ $$aUNRESTRICTED